431 related articles for article (PubMed ID: 16260852)
41. Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01).
Bennouna J; Havel L; Krzakowski M; Kollmeier J; Gervais R; Dansin E; Serke M; Favaretto A; Szczesna A; Cobo M; Ciuffreda L; Jassem J; Nicolini M; Ramlau R; Amoroso D; Melotti B; Almodovar T; Riggi M; Caux NR; Vaissière N; Tan EH
Clin Lung Cancer; 2014 Jul; 15(4):258-65. PubMed ID: 24954228
[TBL] [Abstract][Full Text] [Related]
42. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer.
Masters GA; Drinkard LC; Hoffman PC; Lane N; Watson S; Samuels BL; Bitran JD; Golomb HM; Vokes EE
Cancer J Sci Am; 1995; 1(4):288-94. PubMed ID: 9166490
[TBL] [Abstract][Full Text] [Related]
43. Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer.
Souquet PJ; Fournel P; Bohas CH; Fortune IC; Chatte G
Semin Oncol; 1996 Apr; 23(2 Suppl 5):8-10. PubMed ID: 8610239
[TBL] [Abstract][Full Text] [Related]
44. Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study.
Berghmans T; Ameye L; Willems L; Paesmans M; Mascaux C; Lafitte JJ; Meert AP; Scherpereel A; Cortot AB; Cstoth I; Dernies T; Toussaint L; Leclercq N; Sculier JP;
Lung Cancer; 2013 Nov; 82(2):340-5. PubMed ID: 24007627
[TBL] [Abstract][Full Text] [Related]
45. IL-2, TNF-alpha, and leptin: local versus systemic concentrations in NSCLC patients.
Carpagnano GE; Spanevello A; Curci C; Salerno F; Palladino GP; Resta O; Di Gioia G; Carpagnano F; Foschino Barbaro MP
Oncol Res; 2007; 16(8):375-81. PubMed ID: 17913045
[TBL] [Abstract][Full Text] [Related]
46. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
Pirker R; Pereira JR; Szczesna A; von Pawel J; Krzakowski M; Ramlau R; Vynnychenko I; Park K; Yu CT; Ganul V; Roh JK; Bajetta E; O'Byrne K; de Marinis F; Eberhardt W; Goddemeier T; Emig M; Gatzemeier U;
Lancet; 2009 May; 373(9674):1525-31. PubMed ID: 19410716
[TBL] [Abstract][Full Text] [Related]
47. Chemotherapy with cisplatin and vinorelbine for elderly patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC).
Pereira JR; Martins SJ; Nikaedo SM; Ikari FK
BMC Cancer; 2004 Sep; 4():69. PubMed ID: 15456520
[TBL] [Abstract][Full Text] [Related]
48. A leptin serum concentration less than 10 ng/ml is a predictive marker of outcome in patients with moderate to severe secondary peritonitis.
Bracho-Riquelme RL; Reyes-Romero MA; Pescador N; Flores-García AI
Eur Surg Res; 2008; 41(2):238-44. PubMed ID: 18525209
[TBL] [Abstract][Full Text] [Related]
49. Pretreatment Pokemon Level as a Predictor of Response to Cisplatin and Paclitaxel in Patients with Unresectable Non-Small Cell Lung Cancer.
Zhang QL; Xing XZ; Li FY; Xing YJ; Li J
Oncol Res Treat; 2015; 38(10):496-502. PubMed ID: 26451776
[TBL] [Abstract][Full Text] [Related]
50. Changes in serum inflammatory factors, adiponectin, intestinal flora and immunity in patients with non-small cell lung cancer.
Wang RP; Wang XH; Li ZM; Sun JR
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10566-10572. PubMed ID: 33155213
[TBL] [Abstract][Full Text] [Related]
51. [Expression of serum breast drug-resistance protein in predicting chemosensitivity of NSCLC].
Hu Y; Feng FY; Cheng SJ; Gao YN; Xiao T; Liu YN
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):750-2. PubMed ID: 17366786
[TBL] [Abstract][Full Text] [Related]
52. Serum levels of leptin and proinflammatory cytokines in patients with gastrointestinal cancer.
Dülger H; Alici S; Sekeroğlu MR; Erkog R; Ozbek H; Noyan T; Yavuz M
Int J Clin Pract; 2004 Jun; 58(6):545-9. PubMed ID: 15311551
[TBL] [Abstract][Full Text] [Related]
53. Leptin and TNF-alpha levels in patients with chronic obstructive pulmonary disease and their relationship to nutritional parameters.
Calikoglu M; Sahin G; Unlu A; Ozturk C; Tamer L; Ercan B; Kanik A; Atik U
Respiration; 2004; 71(1):45-50. PubMed ID: 14872110
[TBL] [Abstract][Full Text] [Related]
54. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
[TBL] [Abstract][Full Text] [Related]
55. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
[TBL] [Abstract][Full Text] [Related]
56. The effect of periodontal treatment on serum leptin, interleukin-6, and C-reactive protein.
Shimada Y; Komatsu Y; Ikezawa-Suzuki I; Tai H; Sugita N; Yoshie H
J Periodontol; 2010 Aug; 81(8):1118-23. PubMed ID: 20370420
[TBL] [Abstract][Full Text] [Related]
57. C-reactive protein as a monitor of chemotherapy response in advanced non-small cell lung cancer (CML study).
Srimuninnimit V; Ariyapanya S; Nimmannit A; Wonglaksanapimon S; Akewanlop C; Soparattanapaisarn N
J Med Assoc Thai; 2012 Feb; 95 Suppl 2():S199-207. PubMed ID: 22574550
[TBL] [Abstract][Full Text] [Related]
58. Concurrent low-dose cisplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: a phase II trial with special reference to the hemoglobin level as prognostic parameter.
Pradier O; Lederer K; Hille A; Weiss E; Christiansen H; Schmidberger H; Hess CF
J Cancer Res Clin Oncol; 2005 Apr; 131(4):261-9. PubMed ID: 15616830
[TBL] [Abstract][Full Text] [Related]
59. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma.
O'Brien ME; Saini A; Smith IE; Webb A; Gregory K; Mendes R; Ryan C; Priest K; Bromelow KV; Palmer RD; Tuckwell N; Kennard DA; Souberbielle BE
Br J Cancer; 2000 Oct; 83(7):853-7. PubMed ID: 10970684
[TBL] [Abstract][Full Text] [Related]
60. Effect of intraoperative glucose fluctuation and postoperative IL-6, TNF-α, CRP levels on the short-term prognosis of patients with intracranial supratentorial neoplasms.
Liu TC; Liu QR; Huang Y
Asian Pac J Cancer Prev; 2014; 15(24):10879-82. PubMed ID: 25605194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
